Turning research into something that actually works in the real world sounds straightforward, but it rarely is. There’s a gap between discovery and impact that trips up even the most promising ideas, and it often has less to do with the science and more to do with how the problem is framed, understood, and communicated. My guest today is Marc Filerman, Chief Business Officer at Start2 Group, a global accelerator working across academia, startups, and government to help early-stage ventures de-risk, grow, and scale.

Marc brings a unique perspective shaped by his background as an MIT-trained engineer, corporate leader, and serial startup founder. At Start2 Group, he helps run major programs like BARDA-supported VITAL and NSF-backed Stride Ventures, supporting thousands of companies and contributing to billions in follow-on funding. We talk about what actually separates startups that move forward from those that stall out, including the importance of defining a clear problem, building a real value proposition, and choosing a focused foothold market instead of trying to do everything at once.

We also get into where universities and tech transfer offices have an opportunity to better prepare founders, especially when it comes to early validation and adopting a commercial lens alongside strong IP. Marc shares practical insights on funding pathways beyond venture capital, common mistakes he sees again and again, and how small shifts in thinking can dramatically improve a startup’s chances of success.

In This Episode:

[04:05] Marc shares the three through-lines guiding his career: building things, solving complex problems, and teaching others.

[06:15] He explains his shift from engineering to startups through a passion for translating real-world problems into solutions.

[08:45] Introduction to Start2 Group and its global footprint supporting startup de-risking and commercialization.

[11:20] Breakdown of government-backed programs including BARDA and NSF partnerships, and how they fund innovation.

[14:10] Differences between VITAL (biotech, pandemic preparedness) and STRIDE (deep tech, materials reclamation).

[17:48] A major funding opportunity is highlighted, including a $100M antiviral development initiative.

[21:52] Marc outlines three core startup success factors: clear problem, strong value proposition, and focused market entry.

[24:10] Why poorly defined problem statements derail startups before they gain traction.

[26:30] He explains value propositions as benefits divided by adoption hurdles, not just features or outcomes.

[29:15] Common adoption barriers emerge, especially inertia and resistance to workflow disruption in healthcare systems.

[32:05] The hidden impact of IT integration and organizational complexity on startup adoption.

[34:45] Why many “real problems” never get solved due to low prioritization despite clear need.

[42:33] The importance of choosing a foothold market and resisting the urge to over-expand too early.

[44:10] Academic founders struggle with narrowing focus due to fear of limiting platform potential.

[46:00] Defining a true foothold market as one where customers urgently demand the solution.

[48:10] The biggest gap in university commercialization is lack of early validation and commercial thinking.

[49:20] Tech transfer offices can better support founders by encouraging market validation beyond IP development.

[50:30] Not all startups fit the VC model, alternative funding paths like angels and bootstrapping are critical.

[51:30] Closing reflections on improving startup success through clearer strategy and commercialization readiness.

Resources:

AUTM

Start2

Marc Filerman - LinkedIn